Advertisement

Volume 130, Issue 23

Cover Figure: Hagfish VWF provides insight into mammalian hemostasis See the article by Grant et al.

December 7, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

 

Endogenous fibrinolysis facilitates clot retraction in vivo
This plenary paper provides the first definitive in vivo description of clot retraction. This work also uncovers a novel mechanism/coordination between clot retraction and the fibrinolytic system with potential clinical relevance.

Myeloproliferative neoplasms: from origins to outcomes
This review elegantly details the role of aberrant JAK-STAT signaling in driving the myeloproliferative phenotype and highlights the range of additional mutations in myeloproliferative neoplasms and their role in disease biology.

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia
This article reports a highly specific T-cell prolymphocytic leukemia response to the BCL-2 inhibitor venetoclax in an ex vivo high-throughput drug screen and in 2 refractory patients with a high disease burden.

A critical epithelial survival axis regulated by MCL-1 maintains thymic function in mice
The investigators demonstrate in a conditional knockout mouse model that MCL-1 expression in thymic epithelial cells is critical for medullary epithelial cell survival, maintaining thymic architecture, and supporting thymocyte cell differentiation.

Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
In a succinct and very clinically relevant Perspective, Lenting and colleagues compare the biochemical properties of FVIIIa and the bispecific antibody emicizumab.

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
The authors describe 4 therapeutic agents in this review, including 3 recently approved by the Food and Drug Administration, which will change the landscape of acute myeloid leukemia (AML) therapy.

Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A
This study reveals the critical involvement of splenic marginal zone B cells in initiating immune responses of naive hemophilia A mice to infused FVIII.

When can we stop anticoagulation in patients with cancer-associated thrombosis?
This review explores the benefits and risks of extended anticoagulation in cancer-associated venous thromboembolism and offers expert guidance in this difficult area for clinicians who need to consider the competing risks of thrombosis and bleeding along with mortality and quality of life aspects.

EBV latent membrane protein 2A orchestrates p27kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice
This study addresses an important question in the Epstein-Barr virus (EBV) field: how does the EBV oncoprotein LMP2A cooperate with MYC, a major oncogene targeted by EBV and active in driving EBV-associated lymphomas?

 

This week's complete table of contents

Why Submit to Blood?

 


 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.